| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2017 |
|---|---|---|---|
Revenue | 4,400.7 | 3,462.87 | 1,479.17 |
yoy growth (%) | 27.08 | 134.1 | |
Raw materials | -2,109.21 | -1,491.87 | -509.73 |
As % of sales | 47.92 | 43.08 | 34.46 |
Employee costs | -338.56 | -311.36 | -153.41 |
As % of sales | 7.69 | 8.99 | 10.37 |
Other costs | -442.28 | -357.37 | -191.04 |
As % of sales (Other Cost) | 10.05 | 10.32 | 12.91 |
Operating profit | 1,510.63 | 1,302.26 | 624.98 |
OPM | 34.32 | 37.6 | 42.25 |
Depreciation | -110.29 | -98.78 | -74.14 |
Interest expense | -5.24 | -3.41 | -6.39 |
Other income | 223.94 | 134.77 | 33.56 |
Profit before tax | 1,619.04 | 1,334.85 | 578.01 |
Taxes | -406.88 | -337.84 | -164.28 |
Tax rate | -25.13 | -25.3 | -28.42 |
Minorities and other | 0 | 0 | 0 |
Adj. profit | 1,212.15 | 997 | 413.72 |
Exceptional items | 0 | 0 | 0 |
Net profit | 1,212.15 | 997 | 413.72 |
yoy growth (%) | 21.57 | 140.98 | |
NPM | 27.54 | 28.79 | 27.97 |
The European business reported a 54 percent year on year surge in topline during the quarter.
Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.
The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.
Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.
Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.
Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.
Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
